Compare Booz Allen Hamilton Holding Corporation (BAH) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Charles River Laboratories Intl. Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.51 (market cap $9.45B), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BAH | CRL | |
|---|---|---|
Market Cap | $9.45B | $13.46B |
Sector | Industrials | Health |
52-Week High | $111.63 | $282.00 |
52-Week Low | $59.71 | $145.57 |
Enterprise Value | $13.07B | $16.30B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $78.4, up 0.64% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 68.11% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights its focus on AI and cybersecurity, with a consensus analyst price target of $84.67 suggesting upside potential. Cash flow from operations improved to $1.01 billion in 2025.
The outlook is supported by national security demand and margin expansion, but risks include civil revenue weakness and high leverage. Valuation appears reasonable with a P/E of 12.33. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock offers a dividend yield from recent payouts.
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
